Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (101-110 of 284) with videos related to

Pageof 29
Sort By:
European Journal of Radiology|March 3, 2015
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survivalMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
JCO Precision Oncology|November 25, 2021
Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only SequencingNahed Jalloul, Israel Gomy, Samantha Stokes, et al.
Cancer|April 17, 2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancerPeter C Lo, Suzanne E Dahlberg, Mizuki Nishino, et al.
Lung Cancer (Amsterdam, Netherlands)|April 16, 2004
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access studyPasi A Jänne, Sarada Gurubhagavatula, Beow Y Yeap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancersKimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, et al.
JCO Oncology Practice|November 10, 2025
Biomarker Testing for Non-Small Cell Lung Cancer in Community Practices Operated by an Academic Cancer CenterKarim Farhat, Morgan A Paul, La'Tawnya Roby, et al.
Cancer|November 7, 2008
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year periodPamela M McMahon, Chung Yin Kong, Milton C Weinstein, et al.
Cancer|August 8, 2013
Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activityPaul Beaudry, Jeremy Force, George N Naumov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancerStephanie Cardarella, Atsuko Ogino, Mizuki Nishino, et al.
Pageof 29

Showing results (101-110 of 284) with videos related to

Sort By:
Pageof 29
European Journal of Radiology|March 3, 2015
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survivalMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
JCO Precision Oncology|November 25, 2021
Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only SequencingNahed Jalloul, Israel Gomy, Samantha Stokes, et al.
Cancer|April 17, 2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancerPeter C Lo, Suzanne E Dahlberg, Mizuki Nishino, et al.
Lung Cancer (Amsterdam, Netherlands)|April 16, 2004
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access studyPasi A Jänne, Sarada Gurubhagavatula, Beow Y Yeap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancersKimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, et al.
JCO Oncology Practice|November 10, 2025
Biomarker Testing for Non-Small Cell Lung Cancer in Community Practices Operated by an Academic Cancer CenterKarim Farhat, Morgan A Paul, La'Tawnya Roby, et al.
Cancer|November 7, 2008
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year periodPamela M McMahon, Chung Yin Kong, Milton C Weinstein, et al.
Cancer|August 8, 2013
Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activityPaul Beaudry, Jeremy Force, George N Naumov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancerStephanie Cardarella, Atsuko Ogino, Mizuki Nishino, et al.
Pageof 29